Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group-Reference-Cited by-同舟云学术

Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group

Published:2010-03-07 Issue:5 Volume:54 Page:694-702
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

O'Brien Maureen M.,Lacayo Norman J.,Lum Bert L.,Kshirsagar Smita,Buck Steven,Ravindranath Yaddanapudi,Bernstein Mark,Weinstein Howard,Chang Myron N.,Arceci Robert J.,Sikic Branimir I.,Dahl Gary V.

Funder

NIH

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.22366/fullpdf

Reference35 articles.

1. Childhood and adolescent lymphoid and myeloid leukemia;Pui;Hematol Am Soc Hematol Educ Program,2004

2. Long-term follow-up of relapsed childhood acute lymphoblastic leukemia;Chessells;Br J Haematol,2003

3. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology;Aladjidi;J Clin Oncol,2003